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ABSTRACT
Increasing concern about the emergence of resistance in clinically important pathogens has led to the
establishment of a number of surveillance programmes to monitor the true extent of resistance at the
local, regional and national levels. Although some programmes have been operating for several years,
their true usefulness is only now being realised. This review describes some of the major surveillance
initiatives and the way in which the data have been used in a number of different settings. In the
hospital, surveillance data have been used to monitor local antibiograms and determine infection control
strategies and antibiotic usage policies. In the community, surveillance data have been used to monitor
public health threats, such as infectious disease outbreaks involving resistant pathogens and the effects
of bioterrorism countermeasures, by following the effects of prophylactic use of different antibiotics on
resistance. Initially, the pharmaceutical industry sponsored surveillance programmes to monitor the
susceptibility of clinical isolates to marketed products. However, in the era of burgeoning resistance,
many developers of antimicrobial agents ﬁnd surveillance data useful for deﬁning new drug discovery
and development strategies, in that they assist with the identiﬁcation of new medical needs, allow
modelling of future resistance trends, and identify high-proﬁle isolates for screening the activity of new
agents. Many companies now conduct pre-launch surveillance of new products to benchmark activity so
that changes in resistance can be monitored following clinical use. Surveillance data also represent an
integral component of regulatory submissions for new agents and, together with clinical trial data, are
used to determine breakpoints. It is clear that antibiotic resistance surveillance systems will continue to
provide valuable data to health care providers, university researchers, pharmaceutical companies, and
government and regulatory agencies.
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INTRODUCTION
Antibiotic resistance is often described as a
unidirectional, progressive process associated
with antibiotic use. Typically, antibiotic resistance
arises and increases in incremental steps that are
the result of genetic mutation, the acquisition,
incorporation and expression of exogenous gen-
etic material introduced into a naive genome, or
clonal dissemination. A desire to monitor, model
and predict antibiotic resistance has resulted in
the development and use of surveillance systems
at the local level (primarily hospital-based sys-
tems), as well as regionally, nationally and inter-
nationally. Antibiotic resistance presents an
ongoing challenge in the effective treatment of
patients with infections.
Antibiotic resistance surveillance systems have
several important goals. These include: identify-
ing, understanding and predicting trends in
resistance; detecting the emergence of new resist-
ance mechanisms; developing, implementing and
monitoring the impact of new empirical antibiotic
prescribing, infection control and public health
guidelines; identifying outbreaks of resistant
organisms; assisting in the detection of a bioter-
rorist event; identifying the need for new antibi-
otics (targeted and broad-spectrum agents) and
potential cellular targets for new agents; identify-
ing the need for new diagnostic tests; educating
health care providers, patients and the general
public; and providing data for new drug
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applications (NDAs) and other submissions to
federal licensing agencies (Table 1) [1,2].
Pathogens that have acquired resistance to
antibiotics prescribed currently, or that demon-
strate intrinsic antibiotic resistance to those
agents, or that possess enhanced virulence char-
acteristics continue to emerge. Antibiotic resist-
ance surveillance systems can provide insights
into the areas where resistance is most prevalent,
where the prevalence of resistance is increasing
the fastest, and species which pose the most
signiﬁcant public health threats [2–5]. Given the
potential for variability in resistance, and the
mobility of resistant organisms and resistance
determinants (e.g., plasmids, transposons), the
need for and beneﬁts of local and geographically
broader surveillance can be understood readily.
Access to timely and accurate antibiotic resistance
data may also help to prevent inappropriate
reactions to anecdotal reports of resistance, which
can unfairly bias the perceived efﬁcacy of an
agent, complicate antibiotic strategies, and con-
fuse laboratory testing efforts. In this review, a
brief description of the types of antibiotic resist-
ance surveillance systems available currently will
be followed by an account of the optimal uses of
surveillance systems by health care providers,
university researchers, pharmaceutical and bio-
technology companies, and government and reg-
ulatory agencies.
TYPES OF ANTIBIOTIC RESISTANCE
SURVEILLANCE SYSTEM
Local surveillance systems
All clinical microbiology laboratories that conduct
in-vitro susceptibility testing should disseminate
surveillance data annually, or more frequently, to
all local health care providers and other appro-
priate groups as required. For health care pro-
viders, surveillance data should be collated in the
form of tables that may be constructed according
to National Committee for Clinical Laboratory
Standards (NCCLS) M39-P guidelines [6]. Ideally,
local surveillance consists of continuous tracking
of antibiotic resistance trends among all clinically
relevant isolates tested at an institution, with the
results available to health care providers and
relevant other groups through the publication of
Table 1. Uses of antibiotic resistance surveillance system data by hospitals, university researchers, pharmaceutical
companies and governments
Uses of antibiotic resistance surveillance system data









Guide patient therapy x x
Identify trends in antibiotic resistance: assess the
magnitude of new resistance threats; follow the
dynamics of resistance trends
x x x x x
Detect new resistance mechanisms x x
Monitor impact of empirical prescribing x x x
Monitor effects of infection control interventions x
Identify outbreak of antibiotic-resistant organisms x
Detect bioterrorist events x x x
Monitor antibiotic resistance during the product
development cycle
x x
Identify needs for new antibiotics: monitor the
needs for targeted-spectrum antibiotics
x x
Identify the need for new diagnostic tests and
unmet medical needs
x x
Education and continuing education on antibiotic
resistance
x x x x x
Strategic information to support new antibiotic
drug target development
x x
Identiﬁy high-proﬁle isolates for
antibiotic screens to guide
structure–activity-
relationship strategies for novel targets
x x
Antibiotic resistance modelling x x
Benchmark the activity of new antibiotics; pre-
and post regulatory approval
x x
Regulatory agency submissions such as new drug
applications (NDAs) or other regulatory documents
x x
MIC interpretative criteria submissions (breakpoint
determinations) to government or regulatory agencies
x x
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appropriate reports. Antibiotic susceptibilities
may vary considerably, depending upon the
demographics of the patient population served
by a laboratory (e.g., patients from nursing
homes, intensive care units, community hospitals,
university-afﬁliated teaching hospitals, HIV or
paediatric clinics) and the isolates tested. Resist-
ance data can also be linked to supportive
research programmes in infection control and
antibiotic usage, and may be beneﬁcial in the
development of practical measures designed to
reduce the burden of antibiotic resistance [1].
Surveillance should serve as an early-warning
system, and its usefulness hinges on the rapid
dissemination of information to those concerned
so that timely responsive measures can be initi-
ated. Clinical microbiology laboratories must
communicate antibiotic resistance surveillance
data clearly to health care providers and ensure
that it is received and understood. It is imperative
that local health care providers are aware of local,
regional, national and international surveillance
initiatives, as pathogenic organisms can move
unhindered between hospitals, countries and
continents. Persons involved in political and
public health decisions must respond to changes
in antibiotic resistance patterns and approach
antibiotic resistance as a global problem that
requires local enterprise.
Regional, national and international
surveillance systems
Regional, national and international surveillance
systems use isolates from hospital and reference
clinical microbiology laboratories, as well as state
public health laboratories, to project wide trends
in resistance that may not exist in individual
hospitals, but are important for the awareness of
health care providers. Regional, national and
international antibiotic resistance surveillance
systems must be designed thoughtfully, be well-
maintained, be longitudinal, and involve a con-
sistent and appropriate collaboration of laborat-
ories over time. There are many examples of
regional, national and international surveillance
systems in the USA, Europe and elsewhere. This
review attempts to summarise the types of data
collected and their optimal use. For example, in
the USA, the Active Bacterial Core Surveil-
lance ⁄Emerging Infections Program Network, a
collaboration between the Centers for Disease
Control and Prevention and several state health
departments and universities participating in the
Emerging Infections Program Network, was
designed to estimate the burden of community-
acquired invasive bacterial infections that
manifest typically as sepsis and meningitis [7].
The Active Bacterial Core system determines the
incidence and trends of these diseases in a
multistate population, and uses molecular and
microbiological methods to characterise Strepto-
coccus pneumoniae, Streptococcus pyogenes, Strepto-
coccus agalactiae, Neisseria meningitidis and
Haemophilus inﬂuenzae [7]. Other examples of
government-sponsored programmes in the USA
include the National Nosocomial Infections Sur-
veillance (NNIS) system, and the Intensive Care
Antimicrobial Resistance Epidemiology study, a
subset of hospitals participating in the NNIS
System. The Intensive Care Antimicrobial Resist-
ance Epidemiology study provides data on the
prevalence of antimicrobial resistance and anti-
microbial use in USA hospitals. Antibiotic resist-
ance surveillance studies are also sponsored
commonly by pharmaceutical companies; such
multi-year studies include the Alexander Project
[8], MYSTIC [9], SENTRY [10] and TRUST [11,12].
Other international antibiotic resistance surveil-
lance initiatives include the European Antimicro-
bial Resistance Surveillance System, the Asian
Network for Surveillance of Resistant Pathogens,
and the International Network for the Study of
Emerging Antimicrobial Resistance.
Limitations often exist in multicentre antibiotic
resistance surveillance systems; these include the
absence of timeliness in the publication of data in
peer-reviewed scientiﬁc journals, the lack of
denominator data when considering the relevance
of the resistance rates generated, and the inclu-
sion of duplicate, inappropriately identiﬁed or
clonal strains that can skew surveillance data.
In addition, many surveillance initiatives are
focused narrowly on one or few organisms (e.g.,
Salmonella, Neisseria, Strep. pneumoniae) and a lim-
ited set of test antibiotics, and are not continuous.
Decisions are required to determine which organ-
isms and antibiotics are tested. Resistance rates
reported in centralised studies may depend on
the organisms selected for inclusion and the
number of strains tested. In contrast, decentral-
ised studies may be prone to inter-laboratory
testing errors. Because the cost of centralised
surveillance studies is so high, many such studies
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are supported by the pharmaceutical industry as
post-marketing surveillance. Such studies are, by
necessity, restricted in their focus, with only
particular sites of infection or subsets of organ-
isms represented, and a deﬁned range of antibi-
otics tested, which invariably includes an
investigational or proprietary agent marketed
recently [13]. Ideally, multicentre surveillance
should be representative of all types and sizes of
institutions; however, currently it tends to include
only larger university-afﬁliated hospitals, which
may over-represent the prevalence of resistance
because of the types of patient treated by larger
hospitals. Consideration of the patient isolates
included in any surveillance study is critical to
interpretation of the study, including the way in
which the results might help to control resistance
and facilitate optimal use of the data by health
care providers, university researchers, pharma-
ceutical companies, and government and regula-
tory agencies [14].
OPTIMAL USE OF ANTIBIOTIC
RESISTANCE SURVEILLANCE
SYSTEMS
Hospital and community health care providers
In-vitro activity can be a useful tool, but it does not
necessarily correlate with in-vivo results. The
safety and efﬁcacy of any agent in treating clinical
infections caused by speciﬁc bacterial pathogens
must be established in well-controlled studies.
Regardless of surveillance data or the MIC for an
isolate, patient-, antibiotic- and pathogen-speciﬁc
factors are important in determining the resolu-
tion of a patient’s infection, and there is signiﬁcant
interaction between factors in each of these three
groups. Treatment regimens for patients with
suspected or demonstrated infections should be
developed following consideration of symptoms,
laboratory ﬁndings and relevant medical history,
and in the context of appropriate local and wider
antibiotic resistance trends. Individual in-vitro
susceptibility results may or may not correlate
with clinical outcome, but need to be considered
when treating patients with conﬁrmed or suspec-
ted infections. Very low MICs may predict cure,
but can never guarantee it [15–17]. Resistance can
lead to therapeutic failure, lengthy hospitalisation,
morbidity, and even death. The beneﬁts of MIC
testing during therapy to follow the possible
emergence of resistance in a pathogen, partic-
ularly in the case of patients with serious infec-
tions or who are immunocompromised, have been
demonstrated previously [18,19].
Surveillance for antibiotic susceptibilities pro-
vides health care providers with some, but not all,
information on two (i.e., pathogen and antibiotic)
of the three factors important to patient outcomes.
Many concurrent factors can inﬂuence the out-
come of an infection, only one of which is the
in-vitro susceptibility of the pathogen to the
antibiotic(s) selected for treatment. Antibiotic
prescribing based upon pharmacodynamic prin-
ciples that predict efﬁcacy, predict bacterial erad-
ication, and prevent the emergence of resistance,
are important to the success of therapy [20,21].
The ability to predict resistance in a particular
patient will depend upon the level of resistance to
an antibiotic found in the likely array of patho-
gens in a particular hospital or region. Many less
serious infections will resolve without antibiotic
treatment.
An important consideration for users of any
antibiotic resistance surveillance system is the fact
that sampling bias may be associated with some
samples submitted to clinical laboratories for
diagnostic purposes. Collection of specimens is
affected not only by disease, but also by other
factors, such as patient age. For example, recent
decreases in physician requests for routine urine
cultures for patients with acute cystitis may alter
the spectrum of isolates included in surveillance
data. As the treatment of acute cystitis in other-
wise healthy adult females is now largely empir-
ical, isolates tested in laboratory-based studies
may be predominantly from patients who have
failed previous antibiotic therapy, or from
patients with other underlying risk factors. There-
fore, surveillance data for urinary tract isolates
has the potential to over-represent resistance and
may not be applicable directly to the treatment of
otherwise healthy adult females with uncompli-
cated urinary tract infections [22]. At the other
extreme, it is safe to assume that all blood isolates
and isolates from other sterile sites are tested for
antibiotic susceptibility by clinical microbiology
laboratories. The fact that many hospital antibio-
grams do not differentiate bacterial isolates by
specimen source may also be an important con-
sideration for health care providers. Another
important consideration is that c. 75% of all
antibiotic use in humans is known to be commu-
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nity-based, but surveillance studies obtain their
test isolates primarily from hospital laboratories.
Therefore, are surveillance data relevant for
community-based physicians? Admittedly, many
hospital laboratories accept some specimens
from community-based patients, but the relative
numbers of specimens will depend directly on
local practices and infrastructure, as well as
specimen source, all of which will have an
impact on the pathogens cultured, identiﬁed
and tested for antibiotic susceptibility. Moreover,
most patients who receive antibiotics do not
have specimens submitted for culture, and the
susceptibility of their isolates remains unknown
[1].
University researchers, and pharmaceutical and
biotechnology companies
Identiﬁcation of new medical needs for the discovery
and development of novel antibiotics
Antibiotic surveillance networks can be designed
to capture information that will aid researchers
examining the multifactorial nature of antibiotic
resistance, as well as determining the clinical
signiﬁcance of resistance phenotypes. A better
understanding of established resistance pheno-
types, as well as their niches and evolving
resistance proﬁles, will contribute signiﬁcantly
to the development of derivatives and novel
antibiotics with both directed and extended spec-
tra, as well as diagnostic tests.
Antibiotic resistance is a dynamic phenomenon
that is a major driving force behind antibiotic
drug discovery and development on the part of
industry, and is inﬂuenced by a variety of
different factors imposed by human, bacterial,
viral, fungal and parasitic pathogens. Some of the
common factors that may inﬂuence antibiotic
resistance include changes in medical practice,
advances in medicine, health care ﬁnancing and
health care policies. In the case of human path-
ogens, the commonest factors inﬂuencing antibi-
otic resistance include the genetics, physiology
and ecology of the pathogen. Antibiotic resistance
surveillance systems are important tools for
determining the different resistance categories
that are encountered in clinical practice, which
in turn provides valuable information for new
antibiotic development strategies. Antibiotic
resistance may be either de novo when it develops
in organisms in which resistance to a drug has not
been encountered previously (e.g., vancomycin-
resistant staphylococci), or epidemic when it
results from the ampliﬁcation and spread of a
phenotype encountered previously. Both types of
resistance must be considered and evaluated
when predicting the need for the antibiotics of
the future. Surveillance systems have shown that
the emergence and development of resistance is
unequal for different organisms and does not
correlate easily with drug usage. For example,
Strep. pneumoniae and Staphylococcus aureus show
high rates of resistance to penicillin and oxacillin,
respectively, in the USA. In contrast, Strep. pyo-
genes has remained completely susceptible to
penicillin, despite widespread use of this agent
to treat patients with streptococcal pharyngitis.
Therefore, constant monitoring of antibiotic resist-
ance trends will continue to be a major driving
force behind pharmaceutical strategies to identify
the types of novel antibiotic that will be needed in
the future.
Monitoring antibiotic resistance during the antibiotic
product development cycle
Many strategies for the discovery of new antibac-
terial agents are inﬂuenced by microbial factors
driving the need to discover novel agents that are
active against organisms resistant to currently
available agents [23–25]. Since it can take 12 years
from the discovery of an antibiotic candidate in
the research laboratory to its ﬁnal approval by the
regulatory authorities and launch on to the
market [26], the discovery scientist would beneﬁt
from a crystal ball to be able to predict effectively
new medical needs and resistance mechanisms
that are likely to prevail when the antibiotic is
launched. Therefore, it is important to monitor the
dynamics of resistance throughout the antibiotic
development cycle, since the environment in
which a new product is released may be different
from the resistance environment that was present
when the new chemical entity was discovered.
Antimicrobial surveillance studies conducted at
regular intervals will provide useful data on
resistance trends over time to ensure that the
product still has a viable commercial potential in
terms of meeting medical needs. Even negative
surveillance data will provide valuable informa-
tion for a pharmaceutical developer, and will
assist in decisions to terminate potential products
that show no competitive advantage over agents
marketed currently, or that are no longer effective
506 Clinical Microbiology and Infection, Volume 10 Number 6, June 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 502–511
against target pathogens because of burgeoning
resistance.
Increasingly, it has become apparent that the
effectiveness of some antimicrobial agents cur-
rently available is being eroded by the emergence
of resistance in key pathogens [27,28]. A wide
range of mechanisms have evolved in bacterial
pathogens to enable them to resist the activity of
many different classes of antibiotics. For example,
bacteria can acquire the means to inactivate an
antibiotic, modify the antibiotic target, or export
the antibiotic actively from the cell. In the case of
certain organism and drug combinations, antimi-
crobial surveillance studies are providing a
gloomy picture as it becomes apparent that many
pathogens are not only showing resistance to
single agents, but in certain cases may be multi-
drug resistant, commonly deﬁned as resistance to
three or more different classes of antibiotic
[29,30].
The emergence of resistance to a number of
antibiotics, such as b-lactams, macrolides, quino-
lones and vancomycin, is becoming a major
worldwide health care problem. Many different
antibiotic surveillance initiatives have highlighted
problems associated with emerging resistance in
Gram-positive pathogens. One of the most signi-
ﬁcant challenges has been presented by methicil-
lin-resistant S. aureus, the resistance levels of
which have reached 60% in Japan [31] and 40%
in the USA [32]. The alarming increase in the
prevalence of methicillin-resistant S. aureus was
ﬁrst highlighted by the NNIS system, which
reported rates of 20–40% in the early 1990s. For
enterococci, the NNIS system was effective in
highlighting emerging resistance to vancomycin,
which increased from 0.3% in 1989 to 7.9% in
1993. It is clear that the various antibiotic resist-
ance surveillance systems have been useful to the
pharmaceutical industry in identifying resistant
Gram-positive pathogens as a key area of medical
need in the mid-to-late 1990s. The industry has
risen to the challenge with the recent launch of
products such as quinupristin–dalfoprostin (Sy-
nercid) and linezolid (Zyvox), which are effective
against resistant Gram-positive pathogens, inclu-
ding multi-drug-resistant strains [33–35]. There
are several other promising candidates, such as
daptomycin, oritavancin and dalbavancin, which
are currently in Phase III clinical trials and which
appear to be effective against infections caused by
resistant Gram-positive pathogens.
Although many antibiotic products are avail-
able on the market today, most are effective
against only a small number of targets that are
associated with one or more components of the
bacterial cell wall, or events involved in macro-
molecular (DNA, RNA or protein) biosynthesis.
The last two decades have seen the development
of many structurally related chemical classes (‘me
too’ products) with increased potency or phar-
macokinetic advantages over marketed products
(e.g., newer-generation b-lactams, macrolides and
ﬂuoroquinolones). As a consequence, the micro-
bial population has been subjected to many
closely related chemical analogues, which con-
tribute to the emergence of resistance to many
compounds belonging to the same chemical class.
Surveillance systems have been useful in monit-
oring the activity of structurally related antibiotics
that are directed against these well-known tar-
gets, and the resulting data have been instrumen-
tal in guiding studies to identify new and
improved products. For example, the new
ketolide telithromycin was designed to counter
infections caused by macrolide- and penicillin-
resistant Strep. pneumoniae.
Identiﬁcation of high-proﬁle clinical isolates to support
the discovery and development of novel antibiotics that
evade pre-existing resistance mechanisms
The results from antibiotic resistance surveillance
studies have helped to convince industry to
discover and develop pharmacophores that are
directed against novel targets which are essential
for microbial growth and which show no cross-
resistance to antibiotics currently marketed [36].
The advent of bacterial genomics has resulted in a
paradigm shift for the antibacterial drug discov-
ery scientist in terms of conﬁguring new assays to
screen for hits that are amenable to optimisation
by the medicinal chemist [37–41]. Antibiotic
resistance surveillance systems play a major role
in supporting the discovery scientist by providing
information on the latest clinically relevant phe-
notypes that will need, ultimately, to be covered
by the products that are discovered and devel-
oped. Major advantages of large surveillance
studies include the identiﬁcation of rare or high-
proﬁle isolates that will serve as useful tools for
antibiotic screening or proﬁling of lead molecules.
Valuable isolates for the evaluation of new lead
molecules will include multi-drug-resistant iso-
lates, as well as clinical isolates that show reduced
Critchley and Karlowsky Antibiotic resistance surveillance systems 507
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 502–511
susceptibility to agents launched recently, such as
quinupristin–dalfopristin and linezolid. Surveil-
lance isolates with novel resistance phenotypes
will be useful in supporting studies to determine
the mechanism(s) of resistance, as well as serving
as tools for the proﬁling of new compound leads
in structure–activity relationship studies. For
example, there has been considerable interest in
staphylococcal isolates with reduced susceptibil-
ity to glycopeptide agents such as vancomycin.
The ﬁrst vancomycin-intermediate S. aureus iso-
late was identiﬁed in Japan in 1997, and this was
followed by conﬁrmed reports from the USA and
other countries, including the identiﬁcation of
two fully vancomycin-resistant strains in 2002
[42,43]. Ongoing surveillance initiatives such as
The Surveillance Network (Focus Technologies,
Herndon, VA, USA) play a major role in monit-
oring such phenotypes and ﬂagging them for
conﬁrmation in a reference laboratory. Many
surveillance studies that procure isolates for
testing at a central laboratory also conduct
molecular studies to investigate strains with
reduced susceptibility to marketed agents. For
example, surveillance isolates with deﬁned muta-
tions in the quinolone-resistance-determining re-
gions of the DNA gyrase and topoisomerase
enzymes in S. aureus and Strep. pneumoniae were
used to proﬁle the activity of novel non-ﬂuori-
nated quinolones [44,45].
Furthermore, antibiotic resistance surveillance
studies will continue to play a major role in
supporting discovery scientists in investigation of
the issues associated with the pervasiveness and
heterogeneity of the genomic targets being stud-
ied in large numbers of clinical isolates. It is
apparent that many of the current drug discovery
initiatives have been based on the assumption
that if a novel drug target is present in one isolate,
it is going to be present in all isolates of that
species. However, as the genomes of more and
more organisms become available, it is apparent
that genomic diversity among different strains of
the same species is more widespread than had
been imagined previously [46,47]. For example,
the FabI enzyme, which encodes the enoyl ACP
(acyl carrier protein) reductase in the fatty acid
biosynthetic pathway, has been an attractive
target for the discovery and development of
novel antibiotics [48]. Although novel com-
pounds with inhibitory action against FabI
showed activity against organisms such as
S. aureus, they demonstrated variable activity
against Strep. pneumoniae, certain strains of which
contained a different enzyme, FabK [48]. There-
fore, early evaluation of lead compounds against
an extensive and representative selection of
appropriate recent clinical isolates should be a
necessary prerequisite for clinical development.
These results should be instrumental in convin-
cing any pharmaceutical development committee
that the antibiotic target is pervasive among the
target pathogens, and that any pre-existing resist-
ance mechanisms associated with the antibiotic
development candidate are either not signiﬁcant
or non-existent. Therefore, surveillance systems
not only provide valuable data on resistance and
areas of need, but also provide key isolates with
clinically important phenotypes that serve as
valuable tools for the discovery, evaluation and
optimisation of the novel agents that will be
available in the future.
Surveillance data to model future resistance trends
Recent studies have investigated mathematical
models to predict the effect on resistance of
infection control measures and the impact of calls
for change on the use of antibiotics [49,50]. It is
likely that data from large surveillance studies
conducted over multiple years will be a valuable
component in future models to predict resistance
trends that are likely to arise in the future, and to
conﬁrm or refute those that have been predicted
in the past. The results of such models should
help to direct pharmaceutical scientists involved
in the development of antibiotics to better strate-
gise the types of antimicrobial products that will
be required for the market during the next
5–10 years.
Benchmarking the activity of new antibiotics:
pre- and post-regulatory approval
Surveillance studies are also important in sup-
porting products that are in Phase III clinical
development, and provide a useful component of
NDA submissions seeking to convince the regu-
latory agencies that any pre-existing resistance
mechanisms are either non-existent or low in
frequency. Many pharmaceutical developers now
conduct pre- and post-regulatory approval sur-
veillance studies on their products. Typically, this
involves the collection of key target pathogens
from a geographically distributed network of
hospitals for centralised laboratory testing. The
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resulting data are useful to the pharmaceutical
sponsor, since they provide a benchmark to
monitor any future changes in the susceptibility
of clinically important pathogens to their product
following its regulatory approval and launch, or
to competitor antibiotics following approval and
launch. For example, the TRUST surveillance
studies have been instrumental in tracking activ-
ity of the ﬂuoroquinolone levoﬂoxacin against
key bacterial respiratory pathogens on an annual
basis since its launch in the USA in 1996
[11,12,50,51]. In particular, TRUST results have
been useful in monitoring the activity of levoﬂ-
oxacin against Strep. pneumoniae, an organism that
is under close scrutiny for the emergence of
resistance to ﬂuoroquinolones. The surveillance
results have shown that levoﬂoxacin resistance in
the USA has remained at < 1% after use for
6 years. Surveillance studies are also useful in
putting resistance data into perspective by
providing opportunities to characterise isolates
that have reduced susceptibility or resistance to
the test agent.
Molecular analysis of surveillance isolates has
provided an opportunity to put resistance data
into perspective. Molecular typing by pulsed-ﬁeld
gel electrophoresis of penicillin-resistant pneu-
mococci from Asian children in the Asian Net-
work for Surveillance of Resistant Pathogens
study has shown that the high frequency of
penicillin and multi-drug resistance was associ-
ated with the spread of particular clones in that
region [51,52].
Government and regulatory agencies
Regulatory submissions
Many NDAs include surveillance data showing
the efﬁcacy of the investigational agent against
recent clinical isolates. The data are used to show
that such isolates are susceptible to the investi-
gational antibiotic at the time of approval.
Furthermore, pharmaceutical sponsors use sur-
veillance isolates to show that the investigational
antibiotic is effective against isolates that are
resistant to other classes of antimicrobial agents
(e.g., isolates of S. aureus resistant to linezolid
[53,54] and vancomycin [55,56]). Many NDA
submissions available publically include suscep-
tibility test results for both clinical trial and
surveillance isolates. High-proﬁle isolates with
rare phenotypes identiﬁed in pre-approval sur-
veillance studies are also extremely important
candidates for other studies that, typically,
would be included in an NDA submission on a
new antibiotic (e.g., time-kill kinetics, synergy,
emergence of resistance and post-antibiotic effect
studies). Surveillance studies are also important
for pharmaceutical sponsors seeking an indica-
tion that includes resistant pathogens. Such data,
in combination with clinical trial outcome data,
would be important in convincing the respective
regulatory agency that such an indication is
warranted. In such circumstances, the regulatory
agency may ask the sponsor to provide ongoing
surveillance data to show that the resistance
indication continues to be warranted. A discus-
sion paper from the European Agency for the
Evaluation of Medicinal Products has noted that
some antibiotics are losing their effectiveness
rapidly as resistance is spread within and
between different bacteria. The paper discussed
the need for surveillance systems to gather
reliable data on the prevalence of resistance over
time in different geographical areas. In the USA,
the Food and Drug Administration Task Force on
Antimicrobial Resistance provided key recom-
mendations which highlighted the need for
better surveillance systems, as well as intensive
education for health care professionals and the
public regarding optimal usage of antibiotics.
Interpretative criteria (breakpoint determinations)
In the USA, the NCCLS and the Food and
Drug Administration are agencies involved in
the establishment of breakpoints. The NCCLS
guidance document (M23-A2) recommends that
data for 100 isolates from each organism group
should be presented. The isolates should belong
to clinically relevant species and should include
susceptible and resistant (if recognised) organ-
isms, including isolates with known resistance
mechanisms that are relevant to the agent
being investigated. In most cases, isolates iden-
tiﬁed in surveillance studies will be used in
combination with those identiﬁed in clinical
trials for the assessment of interpretative cri-
teria. Typically, the NCCLS requests disk dif-
fusion and dilution data on at least 500 isolates
tested by NCCLS methods. The MIC ⁄ zone
diameter distributions used for in-vitro test
development should be compared with those
from a large geographically diverse population
of recent clinical isolates.
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CONCLUSIONS
Antimicrobial resistance surveillance systems
have provided useful data for guiding health care
providers, academic researchers, pharmaceutical
developers and governmental agencies. Antibiotic
resistance is clearly a dynamic phenomenon, and
the timely identiﬁcation and reporting of rare
phenotypes is of paramount importance. Surveil-
lance data have been useful in optimising the
careful and prudent use of antibiotics marketed
currently to ensure continued clinical success.
Surveillance and clinical trial data, in concert with
pharmacokinetic data, continue to be important in
the assignment of interpretative criteria (break-
points), especially in cases where agents are being
indicated for therapy of infections caused by
resistant pathogens. Antimicrobial surveillance
data will continue to provide valuable strategic
information to guide the discovery and develop-
ment of novel antibiotic products for the future.
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